Clinical Trials Logo

Cardiac Surgical Procedures clinical trials

View clinical trials related to Cardiac Surgical Procedures.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04760340 Not yet recruiting - Clinical trials for Cardiac Surgical Procedures

TELUS in Cardiac Surgery Patients. Effect of CPB and Relation to Postoperative Events (PORE)Events.

TELUSPORE
Start date: March 1, 2021
Phase:
Study type: Observational [Patient Registry]

Transesophageal Lung ultrasound (TELUS) was described for the first time in 2016. The clinical significance and benefits for the patient of the results of a TELUS examination has not been investigated to date. Since all cardiac surgery with CPB cases in adult patients are performed using a TEE probe to monitor cardiac function, a concomitant TELUS examination is possible in all cases. The study seeks to describe the incidence and severity of the modifications of the aeration of both lungs assessed by TELUS in the perioperative period of adult cardiac surgery and to establish the relation of the TELUS findings with the occurence of postoperative respiratory events (PORE). Eventually, the study will also provide results about the interobserver variation of the TELUS examination for which there no reference to date.

NCT ID: NCT04244981 Not yet recruiting - Clinical trials for Cardiac Surgical Procedures

Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery

Start date: December 1, 2023
Phase: Phase 4
Study type: Interventional

This study is a non-inferiority, randomized controlled trial, based on the hypothesis that 4-factor PCC is not inferior to FFP in reducing perioperative blood loss in patients undergoing cardiac surgery under cardiopulmonary bypass. 796 subjects will be randomly divided into 2 groups (group PCC and group FFP), with 398 cases in each group. Patients will be given 8~15 IU/kg 4-factor PCC in group PCC and 6~10 ml/kg FFP in group FFP. All the patients will be followed up respectively at 24 hours, 48 hours, 72 hours and 7 days after the surgery. The primary outcome is the volume of blood loss within 24 hours after surgery. The secondary outcomes include (1) the total units of allogeneic red blood cells (RBCs) transfused within 7 days after surgery and (2) length of intensive care unit (ICU) stay. Adverse events and serious adverse events will be monitored as safety outcomes. Exploratory outcomes include re-exploration due to postoperative bleeding within 7 days after surgery and length of hospital stay.

NCT ID: NCT01560611 Not yet recruiting - Clinical trials for Cardiac Surgical Procedures

A New Non-invasive Marker to Detect Silent Hypoxia in Patients Undergoing Cardiac Surgery

Start date: March 2012
Phase: N/A
Study type: Observational

In patients undergoing cardiac surgery under cardiopulmonary bypass, some organs like brain and heart are preserved while others (skin, gut and skeletal muscle) are being underperfused. This phenomenon is related to silent peripheral vasoconstriction that is not clinically available but threatens end-organ perfusion and carries the risk of multi-organ failure. By measuring non-invasively the somatic-to-cerebral oxygen saturation gradient, the present study aims at detecting silent peroperative hypoperfusion episodes. The investigators hypothesize that gradient, measured during the surgical procedure, will predict the occurrence of anaerobic metabolism, ascertained by an elevation of blood lactate concentration, measured in intensive care unit.